Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pneumonia, Ventilator-Associated | 88 | 2024 | 279 | 24.770 |
Why?
|
Sepsis | 76 | 2024 | 2603 | 11.430 |
Why?
|
Cross Infection | 61 | 2024 | 1427 | 10.140 |
Why?
|
Infection Control | 41 | 2023 | 984 | 7.470 |
Why?
|
Shock, Septic | 25 | 2024 | 771 | 7.000 |
Why?
|
Respiration, Artificial | 50 | 2024 | 2727 | 5.990 |
Why?
|
Anti-Bacterial Agents | 65 | 2024 | 7474 | 4.550 |
Why?
|
Ventilators, Mechanical | 20 | 2022 | 292 | 4.480 |
Why?
|
Intensive Care Units | 52 | 2024 | 3798 | 3.910 |
Why?
|
Population Surveillance | 34 | 2024 | 2596 | 3.750 |
Why?
|
Respiratory Tract Infections | 8 | 2024 | 1008 | 3.510 |
Why?
|
Electronic Health Records | 39 | 2024 | 4863 | 3.170 |
Why?
|
Pneumonia | 15 | 2023 | 2159 | 3.060 |
Why?
|
Hospitals | 49 | 2024 | 3887 | 2.730 |
Why?
|
Chlorhexidine | 8 | 2022 | 159 | 2.520 |
Why?
|
Masks | 7 | 2023 | 212 | 2.480 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 7 | 2021 | 249 | 2.300 |
Why?
|
Virus Diseases | 5 | 2024 | 720 | 2.290 |
Why?
|
Anti-Infective Agents, Local | 6 | 2018 | 246 | 2.140 |
Why?
|
Community-Acquired Infections | 10 | 2024 | 470 | 2.040 |
Why?
|
Hospital Mortality | 28 | 2024 | 5340 | 1.950 |
Why?
|
Pneumonia, Viral | 11 | 2024 | 3233 | 1.920 |
Why?
|
Disease Transmission, Infectious | 5 | 2022 | 560 | 1.900 |
Why?
|
Critical Care | 21 | 2024 | 2714 | 1.830 |
Why?
|
Humans | 334 | 2024 | 766117 | 1.580 |
Why?
|
Aerosols | 7 | 2024 | 634 | 1.560 |
Why?
|
Influenza, Human | 9 | 2024 | 1542 | 1.500 |
Why?
|
Quality Indicators, Health Care | 9 | 2023 | 1804 | 1.460 |
Why?
|
Coronavirus Infections | 8 | 2020 | 3111 | 1.450 |
Why?
|
Ventilator-Induced Lung Injury | 6 | 2021 | 135 | 1.450 |
Why?
|
Massachusetts | 28 | 2024 | 8882 | 1.430 |
Why?
|
Antibiotic Prophylaxis | 4 | 2024 | 641 | 1.350 |
Why?
|
Communicable Diseases | 6 | 2021 | 873 | 1.320 |
Why?
|
Viruses | 2 | 2024 | 371 | 1.230 |
Why?
|
Communicable Disease Control | 3 | 2020 | 856 | 1.210 |
Why?
|
Respiratory Syncytial Virus Infections | 2 | 2023 | 365 | 1.200 |
Why?
|
Chlamydia Infections | 3 | 2021 | 366 | 1.190 |
Why?
|
Public Health Informatics | 3 | 2020 | 109 | 1.180 |
Why?
|
Drug Resistance, Multiple, Bacterial | 9 | 2021 | 592 | 1.180 |
Why?
|
Disease Notification | 6 | 2022 | 95 | 1.170 |
Why?
|
Sentinel Surveillance | 5 | 2023 | 292 | 1.170 |
Why?
|
Bacteremia | 5 | 2023 | 988 | 1.150 |
Why?
|
Health Personnel | 11 | 2024 | 3387 | 1.130 |
Why?
|
Lyme Disease | 2 | 2024 | 627 | 1.100 |
Why?
|
United States | 86 | 2024 | 72920 | 1.090 |
Why?
|
Pandemics | 20 | 2024 | 8725 | 1.090 |
Why?
|
Algorithms | 20 | 2024 | 14066 | 1.070 |
Why?
|
Critical Illness | 12 | 2023 | 2749 | 1.070 |
Why?
|
Quality Improvement | 11 | 2022 | 3849 | 1.070 |
Why?
|
Inappropriate Prescribing | 4 | 2022 | 211 | 1.050 |
Why?
|
Anti-Infective Agents | 6 | 2023 | 987 | 1.010 |
Why?
|
Intubation, Intratracheal | 6 | 2021 | 1359 | 1.000 |
Why?
|
Clostridium Infections | 5 | 2021 | 563 | 1.000 |
Why?
|
Gram-Negative Bacterial Infections | 3 | 2018 | 239 | 0.980 |
Why?
|
Behavioral Risk Factor Surveillance System | 4 | 2024 | 212 | 0.960 |
Why?
|
Mandatory Programs | 2 | 2022 | 86 | 0.900 |
Why?
|
Metapneumovirus | 1 | 2024 | 28 | 0.900 |
Why?
|
Laboratories | 2 | 2021 | 463 | 0.890 |
Why?
|
Paramyxoviridae Infections | 1 | 2024 | 57 | 0.880 |
Why?
|
Toothbrushing | 1 | 2024 | 48 | 0.880 |
Why?
|
Ralstonia pickettii | 1 | 2022 | 4 | 0.840 |
Why?
|
Burkholderia cepacia | 1 | 2022 | 22 | 0.830 |
Why?
|
Clinical Laboratory Techniques | 4 | 2020 | 746 | 0.820 |
Why?
|
Burkholderia cepacia complex | 1 | 2022 | 24 | 0.820 |
Why?
|
Water Purification | 1 | 2023 | 61 | 0.820 |
Why?
|
Bacterial Infections | 4 | 2021 | 1387 | 0.810 |
Why?
|
Benchmarking | 5 | 2023 | 1055 | 0.800 |
Why?
|
Burkholderia Infections | 1 | 2022 | 41 | 0.800 |
Why?
|
Retrospective Studies | 68 | 2024 | 81565 | 0.800 |
Why?
|
Hemorrhagic Fever, Ebola | 3 | 2016 | 424 | 0.760 |
Why?
|
Pseudomonas Infections | 2 | 2023 | 622 | 0.750 |
Why?
|
Respiratory Syncytial Virus, Human | 1 | 2023 | 150 | 0.740 |
Why?
|
Veterans Health | 1 | 2023 | 216 | 0.740 |
Why?
|
Extracorporeal Membrane Oxygenation | 2 | 2022 | 1480 | 0.740 |
Why?
|
Hospitalization | 23 | 2024 | 10811 | 0.690 |
Why?
|
Benzodiazepines | 2 | 2016 | 1136 | 0.670 |
Why?
|
Air Microbiology | 1 | 2020 | 94 | 0.670 |
Why?
|
Health Policy | 6 | 2022 | 2700 | 0.670 |
Why?
|
Adult | 84 | 2024 | 223139 | 0.670 |
Why?
|
Oral Hygiene | 2 | 2017 | 132 | 0.660 |
Why?
|
Gonorrhea | 2 | 2021 | 355 | 0.660 |
Why?
|
Delayed Diagnosis | 2 | 2020 | 452 | 0.660 |
Why?
|
Societies | 3 | 2019 | 106 | 0.640 |
Why?
|
Pneumonia, Bacterial | 3 | 2016 | 319 | 0.640 |
Why?
|
Incidence | 27 | 2024 | 21513 | 0.640 |
Why?
|
Vancomycin | 2 | 2019 | 504 | 0.630 |
Why?
|
Insurance Claim Review | 2 | 2014 | 744 | 0.610 |
Why?
|
Mouthwashes | 2 | 2018 | 57 | 0.610 |
Why?
|
Male | 99 | 2024 | 363935 | 0.610 |
Why?
|
Delirium | 4 | 2018 | 1699 | 0.600 |
Why?
|
Daptomycin | 1 | 2018 | 71 | 0.600 |
Why?
|
Aged | 66 | 2024 | 171219 | 0.600 |
Why?
|
Female | 100 | 2024 | 396233 | 0.590 |
Why?
|
Indenes | 1 | 2018 | 59 | 0.580 |
Why?
|
Enterococcus faecium | 1 | 2018 | 101 | 0.580 |
Why?
|
Inhalation Exposure | 1 | 2020 | 432 | 0.570 |
Why?
|
Surgical Wound Infection | 4 | 2016 | 1544 | 0.560 |
Why?
|
Practice Guidelines as Topic | 17 | 2024 | 7424 | 0.560 |
Why?
|
Middle Aged | 75 | 2024 | 223083 | 0.560 |
Why?
|
Mass Screening | 4 | 2020 | 5450 | 0.550 |
Why?
|
Severity of Illness Index | 14 | 2022 | 15882 | 0.540 |
Why?
|
Infectious Disease Transmission, Professional-to-Patient | 3 | 2022 | 33 | 0.540 |
Why?
|
Hepatitis B | 3 | 2013 | 709 | 0.540 |
Why?
|
Risk Adjustment | 3 | 2021 | 597 | 0.540 |
Why?
|
Propensity Score | 1 | 2024 | 1973 | 0.530 |
Why?
|
Health Planning | 2 | 2014 | 233 | 0.530 |
Why?
|
Clinical Coding | 5 | 2020 | 187 | 0.510 |
Why?
|
Iatrogenic Disease | 1 | 2019 | 551 | 0.510 |
Why?
|
Guideline Adherence | 5 | 2021 | 2235 | 0.500 |
Why?
|
Catheter-Related Infections | 4 | 2024 | 279 | 0.500 |
Why?
|
Multiple Organ Failure | 6 | 2023 | 389 | 0.490 |
Why?
|
Universal Precautions | 1 | 2014 | 34 | 0.470 |
Why?
|
Government Regulation | 2 | 2022 | 525 | 0.470 |
Why?
|
Glottis | 1 | 2016 | 214 | 0.470 |
Why?
|
Risk Factors | 29 | 2024 | 74857 | 0.460 |
Why?
|
Delivery of Health Care, Integrated | 2 | 2012 | 949 | 0.450 |
Why?
|
Patient Care Management | 2 | 2014 | 301 | 0.450 |
Why?
|
Occupational Exposure | 2 | 2021 | 1806 | 0.450 |
Why?
|
Workplace | 1 | 2020 | 873 | 0.450 |
Why?
|
Medicare | 8 | 2024 | 6820 | 0.450 |
Why?
|
Home Care Services | 2 | 2017 | 659 | 0.450 |
Why?
|
Hypnotics and Sedatives | 3 | 2016 | 1193 | 0.450 |
Why?
|
Ventilator Weaning | 1 | 2015 | 170 | 0.440 |
Why?
|
Length of Stay | 12 | 2024 | 6490 | 0.440 |
Why?
|
Respiratory Insufficiency | 2 | 2021 | 1241 | 0.440 |
Why?
|
Emergency Medical Services | 3 | 2022 | 1937 | 0.430 |
Why?
|
Bronchoalveolar Lavage Fluid | 4 | 2020 | 755 | 0.430 |
Why?
|
Time Factors | 16 | 2024 | 40108 | 0.430 |
Why?
|
Propofol | 2 | 2016 | 607 | 0.420 |
Why?
|
Melatonin | 1 | 2018 | 670 | 0.410 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 6 | 2024 | 705 | 0.410 |
Why?
|
Endocarditis | 1 | 2017 | 349 | 0.410 |
Why?
|
Drug Utilization | 1 | 2019 | 1187 | 0.410 |
Why?
|
Hospital Administration | 1 | 2016 | 351 | 0.410 |
Why?
|
Disease Outbreaks | 6 | 2023 | 1761 | 0.410 |
Why?
|
Observer Variation | 2 | 2016 | 2611 | 0.400 |
Why?
|
Critical Pathways | 1 | 2016 | 475 | 0.400 |
Why?
|
Respiratory Syncytial Viruses | 2 | 2024 | 168 | 0.390 |
Why?
|
Clinical Protocols | 2 | 2017 | 1437 | 0.390 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 2014 | 340 | 0.390 |
Why?
|
Brain Injuries | 1 | 2024 | 2062 | 0.390 |
Why?
|
Occupational Diseases | 1 | 2020 | 1456 | 0.390 |
Why?
|
Prevalence | 14 | 2024 | 15827 | 0.380 |
Why?
|
Risk Management | 1 | 2015 | 558 | 0.380 |
Why?
|
Hepatitis A | 1 | 2012 | 126 | 0.380 |
Why?
|
Neuralgia, Postherpetic | 1 | 2011 | 41 | 0.380 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2015 | 497 | 0.380 |
Why?
|
Dexmedetomidine | 1 | 2016 | 318 | 0.370 |
Why?
|
Conscious Sedation | 1 | 2016 | 534 | 0.370 |
Why?
|
Emergency Service, Hospital | 6 | 2023 | 7871 | 0.340 |
Why?
|
Systemic Inflammatory Response Syndrome | 3 | 2024 | 621 | 0.340 |
Why?
|
Hospitals, Community | 1 | 2012 | 363 | 0.330 |
Why?
|
Ceftazidime | 3 | 2021 | 57 | 0.320 |
Why?
|
Decision Support Systems, Clinical | 2 | 2016 | 1177 | 0.320 |
Why?
|
Silver Compounds | 1 | 2008 | 24 | 0.320 |
Why?
|
Herpes Zoster | 1 | 2011 | 252 | 0.320 |
Why?
|
Diabetes Mellitus, Type 1 | 2 | 2014 | 3445 | 0.310 |
Why?
|
Patient Compliance | 1 | 2019 | 2694 | 0.310 |
Why?
|
HIV Infections | 5 | 2024 | 17535 | 0.300 |
Why?
|
Academic Medical Centers | 6 | 2022 | 2782 | 0.300 |
Why?
|
Pulmonary Edema | 3 | 2016 | 409 | 0.300 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2020 | 2184 | 0.300 |
Why?
|
Urinary Tract Infections | 3 | 2024 | 804 | 0.300 |
Why?
|
Cardiac Surgical Procedures | 1 | 2023 | 3682 | 0.280 |
Why?
|
Equipment Contamination | 1 | 2008 | 183 | 0.280 |
Why?
|
Medical Records Systems, Computerized | 3 | 2014 | 1195 | 0.280 |
Why?
|
Aged, 80 and over | 19 | 2024 | 59515 | 0.280 |
Why?
|
Diabetes Mellitus | 3 | 2022 | 5889 | 0.280 |
Why?
|
Exercise | 2 | 2021 | 5939 | 0.270 |
Why?
|
Health Services Research | 2 | 2015 | 1811 | 0.270 |
Why?
|
Early Diagnosis | 3 | 2020 | 1186 | 0.270 |
Why?
|
Young Adult | 17 | 2024 | 59868 | 0.270 |
Why?
|
Boston | 8 | 2021 | 9335 | 0.270 |
Why?
|
Vaccines | 1 | 2015 | 840 | 0.270 |
Why?
|
Cohort Studies | 16 | 2024 | 41684 | 0.270 |
Why?
|
Water | 2 | 2022 | 1416 | 0.260 |
Why?
|
Surgical Procedures, Operative | 3 | 2016 | 1931 | 0.260 |
Why?
|
Reproducibility of Results | 11 | 2023 | 20137 | 0.250 |
Why?
|
Hypertension | 2 | 2023 | 8616 | 0.250 |
Why?
|
Chronic Disease | 4 | 2024 | 9354 | 0.250 |
Why?
|
Antipsychotic Agents | 1 | 2018 | 3077 | 0.240 |
Why?
|
Adrenal Cortex Hormones | 2 | 2021 | 1882 | 0.240 |
Why?
|
Electronics | 2 | 2023 | 314 | 0.240 |
Why?
|
Diagnostic Errors | 3 | 2020 | 1276 | 0.240 |
Why?
|
Primary Health Care | 5 | 2022 | 4736 | 0.230 |
Why?
|
Asthma | 2 | 2024 | 6268 | 0.230 |
Why?
|
International Classification of Diseases | 3 | 2020 | 934 | 0.230 |
Why?
|
Sensitivity and Specificity | 9 | 2020 | 14645 | 0.220 |
Why?
|
Delivery of Health Care | 7 | 2023 | 5367 | 0.220 |
Why?
|
Staphylococcal Infections | 4 | 2023 | 1393 | 0.220 |
Why?
|
Bacteria | 1 | 2014 | 2212 | 0.220 |
Why?
|
Lactic Acid | 5 | 2021 | 1137 | 0.220 |
Why?
|
Proton Pump Inhibitors | 2 | 2020 | 551 | 0.210 |
Why?
|
Hospitals, University | 3 | 2014 | 573 | 0.210 |
Why?
|
Pulmonary Atelectasis | 2 | 2015 | 160 | 0.210 |
Why?
|
Personnel, Hospital | 2 | 2021 | 285 | 0.200 |
Why?
|
Fluid Therapy | 4 | 2022 | 587 | 0.200 |
Why?
|
Asymptomatic Infections | 2 | 2021 | 137 | 0.200 |
Why?
|
Meta-Analysis as Topic | 2 | 2017 | 1366 | 0.200 |
Why?
|
Carbapenems | 2 | 2020 | 125 | 0.200 |
Why?
|
Rhinovirus | 1 | 2024 | 210 | 0.200 |
Why?
|
Severe Acute Respiratory Syndrome | 2 | 2020 | 136 | 0.200 |
Why?
|
Ice | 1 | 2023 | 102 | 0.200 |
Why?
|
Quality of Health Care | 3 | 2018 | 4306 | 0.200 |
Why?
|
Infant, Newborn | 10 | 2023 | 26381 | 0.200 |
Why?
|
Medical Audit | 4 | 2018 | 454 | 0.190 |
Why?
|
England | 1 | 2023 | 533 | 0.190 |
Why?
|
beta-Lactams | 1 | 2023 | 158 | 0.190 |
Why?
|
Azabicyclo Compounds | 2 | 2021 | 66 | 0.190 |
Why?
|
Reimbursement, Incentive | 2 | 2024 | 541 | 0.190 |
Why?
|
Drug Contamination | 1 | 2022 | 151 | 0.190 |
Why?
|
Information Dissemination | 2 | 2023 | 1142 | 0.180 |
Why?
|
Patient Positioning | 2 | 2016 | 330 | 0.180 |
Why?
|
Ventilation | 1 | 2021 | 129 | 0.180 |
Why?
|
Comorbidity | 5 | 2024 | 10579 | 0.180 |
Why?
|
Adolescent | 15 | 2024 | 88819 | 0.180 |
Why?
|
Child, Preschool | 9 | 2024 | 42511 | 0.180 |
Why?
|
Water-Electrolyte Balance | 1 | 2022 | 326 | 0.180 |
Why?
|
Models, Statistical | 1 | 2015 | 5089 | 0.170 |
Why?
|
Rural Health Services | 1 | 2024 | 393 | 0.170 |
Why?
|
Developing Countries | 1 | 2012 | 2914 | 0.170 |
Why?
|
Hospitals, Teaching | 3 | 2019 | 1156 | 0.170 |
Why?
|
Predictive Value of Tests | 7 | 2020 | 15403 | 0.170 |
Why?
|
Obesity | 3 | 2022 | 13085 | 0.170 |
Why?
|
Regression Analysis | 3 | 2015 | 6324 | 0.160 |
Why?
|
Adenoviridae | 1 | 2024 | 1092 | 0.160 |
Why?
|
Sex Factors | 4 | 2024 | 10614 | 0.160 |
Why?
|
Respiration | 2 | 2016 | 1653 | 0.160 |
Why?
|
Catalysis | 1 | 2021 | 767 | 0.160 |
Why?
|
Reference Values | 3 | 2021 | 4909 | 0.160 |
Why?
|
Immunization, Secondary | 1 | 2022 | 373 | 0.160 |
Why?
|
Child | 12 | 2024 | 80573 | 0.160 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2014 | 12235 | 0.160 |
Why?
|
Public Health | 4 | 2023 | 2681 | 0.160 |
Why?
|
Thromboembolism | 2 | 2016 | 1001 | 0.160 |
Why?
|
Oxygen | 4 | 2024 | 4247 | 0.160 |
Why?
|
Infant | 10 | 2019 | 36427 | 0.150 |
Why?
|
Prospective Studies | 9 | 2023 | 54812 | 0.150 |
Why?
|
Public Health Administration | 3 | 2015 | 242 | 0.150 |
Why?
|
Histamine H2 Antagonists | 1 | 2020 | 168 | 0.150 |
Why?
|
Peptic Ulcer | 1 | 2020 | 214 | 0.150 |
Why?
|
Seasons | 1 | 2024 | 1522 | 0.150 |
Why?
|
Pseudomonas aeruginosa | 2 | 2023 | 1276 | 0.150 |
Why?
|
Corynebacterium Infections | 1 | 2018 | 27 | 0.150 |
Why?
|
Corynebacterium | 1 | 2018 | 49 | 0.150 |
Why?
|
History, 21st Century | 1 | 2024 | 1574 | 0.150 |
Why?
|
Syphilis | 1 | 2021 | 243 | 0.150 |
Why?
|
Substance Withdrawal Syndrome | 1 | 2023 | 627 | 0.150 |
Why?
|
Logistic Models | 7 | 2021 | 13273 | 0.150 |
Why?
|
Respiratory System | 1 | 2021 | 562 | 0.150 |
Why?
|
Tuberculosis | 1 | 2010 | 2010 | 0.140 |
Why?
|
Diagnosis, Differential | 4 | 2021 | 12976 | 0.140 |
Why?
|
Insurance Claim Reporting | 2 | 2017 | 166 | 0.140 |
Why?
|
Inpatients | 3 | 2024 | 2566 | 0.140 |
Why?
|
Pharmacoepidemiology | 1 | 2021 | 351 | 0.140 |
Why?
|
Vasoconstrictor Agents | 2 | 2021 | 653 | 0.140 |
Why?
|
Drug Resistance, Microbial | 1 | 2020 | 832 | 0.140 |
Why?
|
France | 1 | 2018 | 495 | 0.130 |
Why?
|
Amikacin | 1 | 2016 | 48 | 0.130 |
Why?
|
Treatment Outcome | 11 | 2023 | 65219 | 0.130 |
Why?
|
Population Growth | 1 | 2016 | 50 | 0.130 |
Why?
|
Particle Size | 1 | 2020 | 1630 | 0.130 |
Why?
|
Models, Theoretical | 1 | 2008 | 3561 | 0.130 |
Why?
|
Administration, Oral | 3 | 2023 | 4016 | 0.130 |
Why?
|
Colistin | 1 | 2016 | 46 | 0.130 |
Why?
|
Respiratory Therapy | 1 | 2016 | 124 | 0.130 |
Why?
|
Maryland | 1 | 2016 | 278 | 0.130 |
Why?
|
Culture Techniques | 1 | 2016 | 515 | 0.130 |
Why?
|
Patellar Ligament | 1 | 2016 | 65 | 0.130 |
Why?
|
Standard of Care | 1 | 2020 | 568 | 0.120 |
Why?
|
Aortic Aneurysm, Thoracic | 1 | 2002 | 708 | 0.120 |
Why?
|
Drug Combinations | 2 | 2021 | 2076 | 0.120 |
Why?
|
Computer Systems | 2 | 2014 | 468 | 0.120 |
Why?
|
Ulcer | 1 | 2016 | 202 | 0.120 |
Why?
|
Acinetobacter Infections | 1 | 2015 | 74 | 0.120 |
Why?
|
Pennsylvania | 1 | 2016 | 615 | 0.120 |
Why?
|
Buprenorphine | 1 | 2023 | 665 | 0.120 |
Why?
|
Coma | 1 | 2018 | 485 | 0.120 |
Why?
|
Ambulatory Care | 2 | 2019 | 2778 | 0.120 |
Why?
|
Sexually Transmitted Diseases | 1 | 2021 | 668 | 0.120 |
Why?
|
Safety Management | 1 | 2020 | 765 | 0.120 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2022 | 3801 | 0.120 |
Why?
|
Ohio | 1 | 2015 | 320 | 0.120 |
Why?
|
Case-Control Studies | 5 | 2022 | 22228 | 0.120 |
Why?
|
Selection Bias | 1 | 2016 | 359 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2023 | 10380 | 0.110 |
Why?
|
Terminology as Topic | 2 | 2019 | 1536 | 0.110 |
Why?
|
Biota | 1 | 2014 | 23 | 0.110 |
Why?
|
Anti-HIV Agents | 2 | 2021 | 4561 | 0.110 |
Why?
|
Continuity of Patient Care | 1 | 2021 | 1075 | 0.110 |
Why?
|
Sexual Partners | 1 | 2019 | 804 | 0.110 |
Why?
|
Cause of Death | 1 | 2024 | 3715 | 0.110 |
Why?
|
Quarantine | 1 | 2016 | 185 | 0.110 |
Why?
|
Occupational Health | 1 | 2020 | 812 | 0.110 |
Why?
|
Hospitals, Special | 1 | 2014 | 88 | 0.110 |
Why?
|
Influenza Vaccines | 1 | 2021 | 780 | 0.110 |
Why?
|
Antihypertensive Agents | 1 | 2023 | 2028 | 0.110 |
Why?
|
Drainage | 2 | 2017 | 1182 | 0.110 |
Why?
|
Patient Acceptance of Health Care | 2 | 2019 | 3230 | 0.110 |
Why?
|
Probiotics | 1 | 2017 | 387 | 0.110 |
Why?
|
Microbial Sensitivity Tests | 4 | 2022 | 1971 | 0.110 |
Why?
|
Antifungal Agents | 2 | 2016 | 769 | 0.110 |
Why?
|
Acute Disease | 3 | 2012 | 7237 | 0.110 |
Why?
|
Peroneal Nerve | 1 | 2013 | 80 | 0.110 |
Why?
|
Viral Load | 1 | 2022 | 3386 | 0.100 |
Why?
|
Administration, Inhalation | 1 | 2016 | 1154 | 0.100 |
Why?
|
HIV | 1 | 2020 | 1587 | 0.100 |
Why?
|
Patient Care Planning | 1 | 2018 | 903 | 0.100 |
Why?
|
Secondary Prevention | 1 | 2019 | 1470 | 0.100 |
Why?
|
Polyarteritis Nodosa | 1 | 2013 | 70 | 0.100 |
Why?
|
Vaccination | 2 | 2022 | 3431 | 0.100 |
Why?
|
Homosexuality, Male | 1 | 2020 | 1342 | 0.100 |
Why?
|
Computer Security | 1 | 2014 | 261 | 0.100 |
Why?
|
Patient Admission | 2 | 2021 | 1365 | 0.100 |
Why?
|
Informed Consent | 1 | 2018 | 1010 | 0.100 |
Why?
|
Odds Ratio | 4 | 2021 | 9657 | 0.100 |
Why?
|
Drug Administration Routes | 2 | 2021 | 152 | 0.090 |
Why?
|
New York | 1 | 2014 | 880 | 0.090 |
Why?
|
Weight Gain | 1 | 2022 | 2356 | 0.090 |
Why?
|
Posture | 1 | 2015 | 955 | 0.090 |
Why?
|
Trust | 1 | 2016 | 532 | 0.090 |
Why?
|
Bone Transplantation | 1 | 2016 | 920 | 0.090 |
Why?
|
Professional-Patient Relations | 1 | 2016 | 723 | 0.090 |
Why?
|
Area Under Curve | 1 | 2015 | 1638 | 0.090 |
Why?
|
Gait Disorders, Neurologic | 1 | 2013 | 245 | 0.090 |
Why?
|
Poisson Distribution | 1 | 2012 | 507 | 0.090 |
Why?
|
Central Nervous System Fungal Infections | 1 | 2010 | 23 | 0.090 |
Why?
|
Liver Function Tests | 1 | 2012 | 527 | 0.090 |
Why?
|
Diagnosis-Related Groups | 1 | 2012 | 445 | 0.090 |
Why?
|
Comparative Effectiveness Research | 1 | 2016 | 713 | 0.090 |
Why?
|
Hair | 1 | 2014 | 509 | 0.090 |
Why?
|
Carrier State | 1 | 2014 | 529 | 0.090 |
Why?
|
Proportional Hazards Models | 4 | 2019 | 12529 | 0.090 |
Why?
|
Equipment and Supplies | 1 | 2012 | 273 | 0.090 |
Why?
|
Ascomycota | 1 | 2010 | 82 | 0.080 |
Why?
|
Epidemiologic Methods | 1 | 2014 | 1325 | 0.080 |
Why?
|
Silver | 1 | 2010 | 118 | 0.080 |
Why?
|
beta-Lactamases | 2 | 2022 | 308 | 0.080 |
Why?
|
Group Practice | 1 | 2010 | 149 | 0.080 |
Why?
|
Multivariate Analysis | 6 | 2020 | 12061 | 0.080 |
Why?
|
Health Care Costs | 2 | 2020 | 3243 | 0.080 |
Why?
|
Risk | 3 | 2021 | 9599 | 0.080 |
Why?
|
Blood Transfusion | 1 | 2015 | 1307 | 0.080 |
Why?
|
Documentation | 1 | 2015 | 911 | 0.080 |
Why?
|
North Carolina | 2 | 2019 | 329 | 0.080 |
Why?
|
Healthcare Disparities | 1 | 2024 | 3407 | 0.080 |
Why?
|
Health Behavior | 2 | 2017 | 2649 | 0.080 |
Why?
|
Age Distribution | 3 | 2019 | 2865 | 0.080 |
Why?
|
Patient Discharge | 3 | 2023 | 3465 | 0.080 |
Why?
|
Confidence Intervals | 1 | 2014 | 2915 | 0.080 |
Why?
|
Immunoglobulins | 2 | 2021 | 853 | 0.080 |
Why?
|
Lung Transplantation | 1 | 2018 | 1310 | 0.080 |
Why?
|
Disinfection | 1 | 2010 | 207 | 0.070 |
Why?
|
Opioid-Related Disorders | 1 | 2023 | 2177 | 0.070 |
Why?
|
Health Maintenance Organizations | 1 | 2010 | 655 | 0.070 |
Why?
|
Patient Care Team | 2 | 2016 | 2517 | 0.070 |
Why?
|
Review Literature as Topic | 1 | 2009 | 297 | 0.070 |
Why?
|
Urinary Catheterization | 1 | 2008 | 195 | 0.070 |
Why?
|
Pregnancy | 2 | 2020 | 30233 | 0.070 |
Why?
|
Risk Assessment | 6 | 2021 | 24276 | 0.070 |
Why?
|
Drug Therapy, Combination | 1 | 2017 | 6309 | 0.070 |
Why?
|
Gentian Violet | 1 | 2007 | 25 | 0.070 |
Why?
|
Attitude to Health | 1 | 2016 | 2020 | 0.070 |
Why?
|
Phenazines | 1 | 2007 | 53 | 0.070 |
Why?
|
ROC Curve | 1 | 2015 | 3614 | 0.070 |
Why?
|
Immunoglobulin M | 1 | 2012 | 1527 | 0.070 |
Why?
|
Resuscitation | 2 | 2021 | 681 | 0.070 |
Why?
|
Immunocompromised Host | 3 | 2019 | 865 | 0.070 |
Why?
|
RNA, Messenger | 1 | 2021 | 12775 | 0.070 |
Why?
|
Recurrence | 1 | 2019 | 8494 | 0.070 |
Why?
|
Survival Analysis | 1 | 2018 | 10087 | 0.060 |
Why?
|
Age Factors | 3 | 2019 | 18386 | 0.060 |
Why?
|
Follow-Up Studies | 3 | 2018 | 39243 | 0.060 |
Why?
|
Transplantation, Homologous | 1 | 2014 | 4860 | 0.060 |
Why?
|
Referral and Consultation | 1 | 2018 | 3617 | 0.060 |
Why?
|
Data Collection | 1 | 2014 | 3318 | 0.060 |
Why?
|
Bacteriological Techniques | 2 | 2016 | 276 | 0.060 |
Why?
|
Anesthesia | 1 | 2015 | 1595 | 0.060 |
Why?
|
Quality Assurance, Health Care | 2 | 2018 | 2171 | 0.060 |
Why?
|
Clinical Trials as Topic | 2 | 2020 | 8038 | 0.060 |
Why?
|
Medical Records | 1 | 2010 | 1408 | 0.060 |
Why?
|
Bayes Theorem | 2 | 2024 | 2353 | 0.060 |
Why?
|
Body Mass Index | 3 | 2022 | 13046 | 0.060 |
Why?
|
Biofilms | 1 | 2008 | 641 | 0.060 |
Why?
|
Frontal Lobe | 1 | 2010 | 1408 | 0.060 |
Why?
|
Monobactams | 1 | 2023 | 16 | 0.050 |
Why?
|
Patient Isolators | 1 | 2023 | 11 | 0.050 |
Why?
|
Louisiana | 1 | 2023 | 104 | 0.050 |
Why?
|
Indiana | 1 | 2023 | 93 | 0.050 |
Why?
|
Registries | 2 | 2020 | 8347 | 0.050 |
Why?
|
Drug Administration Schedule | 2 | 2021 | 4853 | 0.050 |
Why?
|
Double-Blind Method | 1 | 2017 | 12426 | 0.050 |
Why?
|
Catheterization, Central Venous | 1 | 2008 | 538 | 0.050 |
Why?
|
Insurance, Health | 1 | 2015 | 2520 | 0.050 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 5531 | 0.050 |
Why?
|
Aspergillus | 1 | 2023 | 93 | 0.050 |
Why?
|
Enterobacter | 1 | 2022 | 44 | 0.050 |
Why?
|
Oseltamivir | 1 | 2022 | 76 | 0.050 |
Why?
|
Myocardial Infarction | 1 | 2022 | 11509 | 0.050 |
Why?
|
Neoplasms | 2 | 2021 | 22344 | 0.050 |
Why?
|
Feasibility Studies | 1 | 2012 | 5300 | 0.050 |
Why?
|
Glucagon | 1 | 2003 | 533 | 0.050 |
Why?
|
Heart Failure | 2 | 2022 | 11837 | 0.050 |
Why?
|
Visitors to Patients | 1 | 2020 | 36 | 0.040 |
Why?
|
Software | 1 | 2014 | 4463 | 0.040 |
Why?
|
Drug Resistance, Bacterial | 2 | 2020 | 1065 | 0.040 |
Why?
|
Acute Kidney Injury | 1 | 2012 | 1943 | 0.040 |
Why?
|
Hospital Bed Capacity | 1 | 2021 | 200 | 0.040 |
Why?
|
Rats | 1 | 2016 | 23717 | 0.040 |
Why?
|
Bronchoalveolar Lavage | 1 | 2020 | 131 | 0.040 |
Why?
|
Longitudinal Studies | 1 | 2016 | 14747 | 0.040 |
Why?
|
Medically Underserved Area | 1 | 2022 | 267 | 0.040 |
Why?
|
Death Certificates | 1 | 2020 | 172 | 0.040 |
Why?
|
Renal Replacement Therapy | 1 | 2021 | 282 | 0.040 |
Why?
|
Bronchitis, Chronic | 1 | 2019 | 81 | 0.040 |
Why?
|
Cardiotonic Agents | 1 | 2021 | 540 | 0.040 |
Why?
|
Infusions, Intravenous | 1 | 2023 | 2227 | 0.040 |
Why?
|
Gastrointestinal Agents | 1 | 2003 | 511 | 0.040 |
Why?
|
Opiate Substitution Treatment | 1 | 2023 | 452 | 0.040 |
Why?
|
Mental Disorders | 1 | 2018 | 6871 | 0.040 |
Why?
|
Australia | 1 | 2022 | 1260 | 0.040 |
Why?
|
Medical History Taking | 1 | 2002 | 779 | 0.040 |
Why?
|
Paralysis | 1 | 2019 | 248 | 0.040 |
Why?
|
Coronavirus | 1 | 2020 | 155 | 0.040 |
Why?
|
CD4 Lymphocyte Count | 1 | 2024 | 2586 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2023 | 1729 | 0.040 |
Why?
|
Disease Management | 2 | 2018 | 2531 | 0.040 |
Why?
|
Plasmids | 1 | 2022 | 2267 | 0.040 |
Why?
|
Gram-Negative Bacteria | 1 | 2018 | 275 | 0.030 |
Why?
|
Disease Models, Animal | 1 | 2016 | 18321 | 0.030 |
Why?
|
Fluoroquinolones | 1 | 2018 | 307 | 0.030 |
Why?
|
Erythrocyte Transfusion | 1 | 2021 | 574 | 0.030 |
Why?
|
Skilled Nursing Facilities | 1 | 2021 | 407 | 0.030 |
Why?
|
Genomics | 2 | 2023 | 5926 | 0.030 |
Why?
|
Cross-Sectional Studies | 3 | 2024 | 26290 | 0.030 |
Why?
|
Hypoglycemia | 1 | 2003 | 896 | 0.030 |
Why?
|
Physical Examination | 1 | 2002 | 1263 | 0.030 |
Why?
|
Intensive Care Units, Neonatal | 1 | 2023 | 858 | 0.030 |
Why?
|
Acinetobacter | 1 | 2015 | 39 | 0.030 |
Why?
|
China | 1 | 2022 | 2383 | 0.030 |
Why?
|
Thinness | 1 | 2019 | 482 | 0.030 |
Why?
|
Radiography, Thoracic | 1 | 2002 | 1319 | 0.030 |
Why?
|
Dexamethasone | 1 | 2023 | 1962 | 0.030 |
Why?
|
Linear Models | 2 | 2018 | 5873 | 0.030 |
Why?
|
Chest Pain | 1 | 2002 | 1102 | 0.030 |
Why?
|
Biomedical Research | 1 | 2010 | 3458 | 0.030 |
Why?
|
Inservice Training | 1 | 2017 | 375 | 0.030 |
Why?
|
Hepatitis, Viral, Human | 1 | 2015 | 141 | 0.030 |
Why?
|
Pulmonary Emphysema | 1 | 2019 | 683 | 0.030 |
Why?
|
Animals | 2 | 2016 | 168800 | 0.030 |
Why?
|
Databases, Factual | 2 | 2020 | 8062 | 0.030 |
Why?
|
Survival Rate | 2 | 2021 | 12827 | 0.030 |
Why?
|
Intention | 1 | 2016 | 346 | 0.030 |
Why?
|
Surgery Department, Hospital | 1 | 2014 | 170 | 0.030 |
Why?
|
Hepatitis B Core Antigens | 1 | 2013 | 90 | 0.030 |
Why?
|
Staphylococcus aureus | 1 | 2021 | 1423 | 0.030 |
Why?
|
Causality | 1 | 2019 | 1247 | 0.030 |
Why?
|
Genome, Bacterial | 1 | 2018 | 796 | 0.030 |
Why?
|
Stress, Physiological | 1 | 2020 | 1405 | 0.020 |
Why?
|
Prognosis | 3 | 2019 | 29912 | 0.020 |
Why?
|
Culture | 1 | 2016 | 622 | 0.020 |
Why?
|
Automation | 1 | 2014 | 585 | 0.020 |
Why?
|
Inflammation Mediators | 1 | 2020 | 1890 | 0.020 |
Why?
|
Neural Conduction | 1 | 2013 | 442 | 0.020 |
Why?
|
Oral Health | 1 | 2017 | 493 | 0.020 |
Why?
|
Sex Distribution | 1 | 2016 | 2270 | 0.020 |
Why?
|
Glucose | 1 | 2003 | 4335 | 0.020 |
Why?
|
Hemodynamics | 1 | 2021 | 4188 | 0.020 |
Why?
|
Pilot Projects | 1 | 2024 | 8724 | 0.020 |
Why?
|
Intensive Care Units, Pediatric | 1 | 2017 | 1021 | 0.020 |
Why?
|
Muscle Weakness | 1 | 2013 | 412 | 0.020 |
Why?
|
Cost of Illness | 1 | 2019 | 1949 | 0.020 |
Why?
|
beta-Glucans | 1 | 2010 | 129 | 0.020 |
Why?
|
Program Evaluation | 1 | 2018 | 2502 | 0.020 |
Why?
|
Evolution, Molecular | 1 | 2018 | 1889 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2022 | 3068 | 0.020 |
Why?
|
Histocytochemistry | 1 | 2010 | 695 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2020 | 6506 | 0.020 |
Why?
|
Bacterial Proteins | 1 | 2022 | 3830 | 0.020 |
Why?
|
Education, Medical, Continuing | 1 | 2014 | 829 | 0.020 |
Why?
|
Patient Selection | 1 | 2020 | 4249 | 0.020 |
Why?
|
Morbidity | 1 | 2013 | 1753 | 0.020 |
Why?
|
Tuberculosis, Pulmonary | 1 | 2015 | 836 | 0.020 |
Why?
|
California | 1 | 2011 | 1435 | 0.020 |
Why?
|
Mental Health | 1 | 2022 | 3273 | 0.020 |
Why?
|
Blood Glucose | 1 | 2021 | 6421 | 0.020 |
Why?
|
Analgesics, Opioid | 1 | 2023 | 3836 | 0.020 |
Why?
|
Urban Population | 1 | 2014 | 2040 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2021 | 4054 | 0.020 |
Why?
|
Mortality | 1 | 2017 | 2911 | 0.020 |
Why?
|
Fever | 1 | 2013 | 1607 | 0.020 |
Why?
|
Phenotype | 1 | 2023 | 16716 | 0.020 |
Why?
|
Microscopy | 1 | 2010 | 900 | 0.020 |
Why?
|
Triazoles | 1 | 2010 | 902 | 0.010 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2015 | 1188 | 0.010 |
Why?
|
Cluster Analysis | 1 | 2011 | 2718 | 0.010 |
Why?
|
Coronary Artery Bypass | 1 | 2013 | 2188 | 0.010 |
Why?
|
Injections, Subcutaneous | 1 | 2003 | 683 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2014 | 7843 | 0.010 |
Why?
|
Natural Language Processing | 1 | 2008 | 1198 | 0.010 |
Why?
|
Radiography | 1 | 2010 | 6943 | 0.010 |
Why?
|
Pyrimidines | 1 | 2010 | 3050 | 0.010 |
Why?
|
Pain | 1 | 2013 | 5090 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2010 | 4213 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2008 | 3690 | 0.010 |
Why?
|
Kidney Transplantation | 1 | 2010 | 4277 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2010 | 36548 | 0.000 |
Why?
|